EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallbericht

Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review

A Kahvecioglu, S Kilickap, P Hurmuz

Cancer/Radiothérapie · 2023

DOI: 10.1016/j.canrad.2023.06.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer/Radiothérapie, 2023. Verfasst von A Kahvecioglu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hacettepe University, Faculty of Medicine, Department of Radiation Oncology, 06100 Sihhiye, Ankara, Turkey. Electronic address: alperkahvecioglu3@gma…. Hauptthemen laut MEDLINE: Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although tyrosine kinase inhibitors (TKI) have revolutionized the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALKr-NSCLC), radiotherapy (RT) still plays an essential role for treatment of both intracranial and extracranial metastases, particularly for patients experienced a TKI-failure. We reported the case of a 38-year-old woman with metastatic ALKr-NSCLC who received whole-brain radiotherapy (RT) for multiple brain metastases (BMs), initially. After RT, alectinib was initiated and the patient had a good clinico-radiological response in both intracranial and extracranial regions. However, intracranial progression was developed and, stereotactic radiosurgery (SRS) was applied to the four progressed BMs. Two months after SRS, all BMs disappeared. While patient was using alectinib, a recurrent lung lesion, a hilar lymph node and bone metastasis were detected. Stereotactic body radiotherapy (SBRT) was applied to all metastatic sites and, alectinib was continued again. Three months after SBRT, a complete response was obtained. She has been alive with the initial systemic therapy agent for more than 4years without evidence of neither disease nor toxicity. SRS/SBRT may eradicate the TKI-resistant tumoral clones and it may prevent switching the systemic therapy, even if there is a failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsRadiosurgeryAdultFemaleHumansBrainProtein Kinase InhibitorsRetrospective Studies

Stichwörter der Autor:innen

AlectinibBrain metastasisCancer du poumonLung cancerMétastases cérébralesRadiotherapyRadiothérapie

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Hacettepe University, Faculty of Medicine, Department of Radiation Oncology, 06100 Sihhiye, Ankara, Turkey. Electronic address: alperkahvecioglu3@gmail.com.
  • Istinye University, Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey. Electronic address: saadettin.kilickap@istinye.edu.tr.
  • Hacettepe University, Faculty of Medicine, Department of Radiation Oncology, 06100 Sihhiye, Ankara, Turkey. Electronic address: phurmuz@yahoo.com.tr.

Zitieren

APA

Kahvecioglu, A., Kilickap, S., & Hurmuz, P. (2023). Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2023.06.002

Vancouver

Kahvecioglu A, Kilickap S, Hurmuz P. Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review. Cancer/Radiothérapie. 2023. doi:10.1016/j.canrad.2023.06.002

BibTeX
@article{Kahvecioglu2023,
  author = {Kahvecioglu, A and Kilickap, S and Hurmuz, P},
  title = {Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review},
  journal = {Cancer/Radiothérapie},
  year = {2023},
  doi = {10.1016/j.canrad.2023.06.002}
}
Kostenlos starten →